Drugs Made In America Acquisition

DMAA · NASDAQ

$10.88−$0.005 (−0.05%)TodayMarket closed · Oct 23, 4:01 PM ET

Prev close $10.88

About DMAA

Drugs Made In America Acquisition Corp. is a blank check company, which engages in the provision of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-01-28. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The firm intends to focus its search for businesses in the pharmaceutical industry. The firm has neither engaged in any operations nor generated any revenues.

Employees: 0
Headquarters: Fort Lauderdale, Florida
Listed: Jan 28, 2025
Sector: N/A
Industry: N/A
Website: dmaacorp.com

Leadership

Drugs Made In America Acquisition executives
Name	Title	Since	Age
Lynn Stockwell	—	2024	69
Saleem Elmasri	—	—	39
Catherine Do	—	—	44
G. Sridhar Prasad	—	—	61
Myron Shulgan	—	—	78

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.